TITLE

Bayer Schering job cuts

AUTHOR(S)
William, Dede; Gibson, Jane
PUB. DATE
March 2007
SOURCE
ICIS Chemical Business Americas;3/5/2007, Vol. 271 Issue 9, p13
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
This article reports that Schering is set to cut 950 jobs at its headquarters in Berlin, Germany by 2009. Werner Wenning, Bayer chairman, said the move is due to the merger between the pharmaceutical activities of Schering and Bayer. Wenning, who is also chairman of Bayer Schering Pharma's supervisory board, said 350 Berlin employees have been offered early retirement or voluntary redundancy with severance pay.
ACCESSION #
24392046

 

Related Articles

  • New step for Bayer Schering.  // R&D Magazine;Jan2007, Vol. 49 Issue 1, p12 

    The article reports that Schering has been renamed to Bayer Schering Pharma AG following its acquisition by Bayer AG in July 2006. According to Werner Wenning, Bayer AG management board chairman, the firm is focusing on the next steps. Bayer Schering Pharma AG together with Bayer's...

  • Bayer's Schering buy good move. Williams, Dede // ICIS Chemical Business;12/4/2006, Vol. 1 Issue 46, p10 

    The article focuses on the statement by Bayer chairman Werner Wenning regarding the impact of the acquisition of German drug maker Schering by Bayer. The consolidation of Schering contributed strongly to the expansion of quarterly sales, and Wenning said the takeover will boost full-year...

  • Bayer completes acquisition of U.S biologics manufacturing facility from Novartis.  // Chemical Business;Oct2007, Vol. 21 Issue 10, p75 

    The article reports on the acquisition by Bayer of a biologics manufacturing facility in California from Novartis in October 2007. Under the deal, the drug Betaseron will be manufactured by Bayer, retain all employees involved in the production of the drug. Reportedly, Novartis has also...

  • Europe watch.  // ICIS Chemical Business Americas;3/26/2007, Vol. 271 Issue 12, p14 

    The article presents news briefs on chemical producer Bayer as of March 2007. The company reached an agreement with the works council at the Bayer Schering Pharma on an acceptable plan for implementing its job cuts after their merger. Bayer paid $1.2 billion as settlement for 3,152 out-of-court...

  • Schering renamed.  // European Pharmaceutical Executive;Feb/Mar2007, p10 

    The article reports on Germany-based Schering AG's decision to change its name to Bayer Schering Pharma AG. The necessary entry in the commercial register took effect on December 29, 2006. The article also reports that the new logo has been mounted on Bayer Schering Pharma's headquarters in...

  • Schering cuts save €700m/year. Robinson, Simon; Williams, Dede // ICIS Chemical Business;6/26/2006, Vol. 1 Issue 25, p10 

    The article reports on the takeover of Schering by Bayer in June 2006. The takeover is considered the biggest and the most expensive deal in the company's history. At a joint news conference, Werner Wenning of Bayer rejected suggestions that Bayer had not moved fast enough to thwart Merck by...

  • Bayer aims high for its 2009 targets. Williams, Dede; Watts, Mark // ICIS Chemical Business;3/19/2007, Vol. 2 Issue 58, p5 

    The article reveals that after buying Schering, Bayer has lifted its 2009 targets for earnings, capital expenditure, and research and development. According to Chairman Werner Wenning, Bayer's management is targeting an underlying margin of 22% for earnings before interest, tax, depreciation and...

  • NewCo attracts offers to buy...  // European Chemical News;12/1/2003, Vol. 79 Issue 2079, p7 

    Reports on the offers to acquire NewCo received by Bayer, according to its chairman Werner Wenning. Plans of Bayer for NewCo; Spinoff plans of Bayer; Speculations concerning the plan of Bayer for NewCo.

  • Jump in profits for Bayer exceeds expectations.  // European Chemical News;5/12/2003, Vol. 78 Issue 2052, p6 

    Deals with the profit growth posted by Bayer for the first quarter of 2003. Factors attributed to the profit growth; Effect of the Aventis CropScience acquisition on the company's sales performance; Comments from Werner Wenning, company chairman.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics